Table 1.

Eligibility criteria for participants

Inclusion criteria  ► PCOS as diagnosed by the Rotterdam criteria  ► BMI ≥ 30 kg/m2  ► Age 18–45 years  ► Informed written consent

Exclusion criteria  ► Patients diagnosed with any known serious chronic illness, including type 1 or 2 diabetes (or a randomly measured fasting plasma glucose > 7 mmol/l)  ► Angina pectoris, coronary heart disease or congestive heart failure (NYHA Classes III–IV)  ► Severe renal impairment (creatinine clearance (GFR) < 30 mL/min)  ► Severe hepatic impairment  ► Inflammatory bowel disease  ► Gastroparesis  ► Cancer  ► Chronic obstructive lung disease  ► Psychiatric disease, a history of major depressive or other severe psychiatric disorders  ►Bleeding diathesis or anticoagulant treatment  ► Current or history of neurological disease including traumatic brain injury  ► Contraindications for MR scanning (implants, claustrophobia, etc.)  ► The use of medications that cause clinically significant weight gain or loss  ► Previous bariatric surgery  ► A history of idiopathic acute pancreatitis  ► A family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma  ► Current smoking  ► Pregnancy, expecting pregnancy or breastfeeding  ► Allergy to any of the ingredients of the study medication: semaglutide, disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid and sodium hydroxide  ► Anticipated change in lifestyle (e.g. eating, exercise or sleeping pattern) during the trial  ► Any condition that the investigator feels would interfere with trial participation (such as inability to follow frequent trial visits according to protocol schedule)

Abbreviations: PCOS polycystic ovary syndrome, BMI body mass index, GFR glomerular filtration rate, MR scanning magnetic resonance scanning